Company Profile
CRISPR Therapeutics Stock Price, News & Analysis
- Ticker:
- CRSP
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- Switzerland with major U
Stock performance
51.64 USD (-1.54%)
Close
Last updated: August 6, 2026
5.02B USD
Market cap
Why the stock is moving
As of Aug 6, 2026, CRSP closed down 1.54% at $51.64. No new same-company headline was identified in the current news window.
Company overview
Gene-Based Medicine Platform
CRISPR Therapeutics develops gene-edited medicines across hemoglobinopathies, cardiovascular disease, autoimmune disease, oncology, regenerative medicine and rare disease. Its toolkit includes CRISPR/Cas9, the SyNTase editing platform, lipid-nanoparticle delivery and engineered cell therapies.
CASGEVY
CASGEVY is an ex vivo CRISPR-edited autologous stem-cell therapy approved for eligible patients with sickle cell disease and transfusion-dependent beta thalassemia. Vertex leads manufacturing and commercialization, while the companies share program economics.
In Vivo Liver Editing
The liver-directed portfolio includes CTX310 against ANGPTL3 for severe lipid disorders, CTX340 against angiotensinogen for refractory hypertension, CTX321 against LPA and CTX460 against SERPINA1 for alpha-1 antitrypsin deficiency. These programs use lipid nanoparticles to perform editing directly in patients.
Zugo-Cel
Zugo-cel is an off-the-shelf CD19 CAR-T therapy engineered with CRISPR for immune evasion and potency. It is being evaluated across rheumatologic, hematologic and neurologic autoimmune diseases as well as B-cell malignancies.
RNA Therapeutics
Through a collaboration with Sirius Therapeutics, the company is developing CTX611, a long-acting Factor XI siRNA for thromboembolic disorders. The candidate is in Phase 2 testing in patients undergoing total knee arthroplasty.
Regenerative Medicine
CTX213 is a deviceless, gene-edited beta-cell replacement candidate for type 1 diabetes. The program uses edited induced pluripotent stem cells to create unencapsulated precursor islet cells intended to restore insulin production.
Future catalysts
FDA review milestones for the pediatric CASGEVY submission covering patients ages 5–11.
CTX340 clinical-trial initiation planned in the first half of 2026 and CTX460 trial initiation planned for mid-2026.
Clinical update from the Phase 1b CTX310 program expected in the second half of 2026.
Updates from the zugo-cel autoimmune and B-cell malignancy programs expected in the second half of 2026.
Phase 2 CTX611 update expected in the second half of 2026.
Recent news
- 01
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results
Source: CRISPR Therapeutics
- 02
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
Source: CRISPR Therapeutics
- 03
CRISPR Therapeutics to Present at the Bank of America Securities 2026 Global Healthcare Conference
Source: CRISPR Therapeutics
- 04
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results
Source: CRISPR Therapeutics
- 05
CRISPR Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
Source: CRISPR Therapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of CRISPR Therapeutics (CRSP)?
CRISPR Therapeutics (CRSP) most recently closed at 51.64 USD, a -1.54% move versus the previous session.
What is the market cap of CRISPR Therapeutics (CRSP)?
CRISPR Therapeutics currently has a market capitalization of 5.02B USD on BioPharmSignal.
What does CRISPR Therapeutics do?
Gene-Based Medicine Platform CRISPR Therapeutics develops gene-edited medicines across hemoglobinopathies, cardiovascular disease, autoimmune disease, oncology, regenerative medicine and rare disease. Its toolkit includes CRISPR/Cas9, the SyNTase editing platform, lipid-nanoparticle delivery and engineered cell therapies. CASGEVY CASGEVY is an ex vivo...
On which exchange is CRSP stock listed?
CRISPR Therapeutics (CRSP) is associated with NASDAQ, Switzerland with major U, Biopharma.
What is CAR-T?
Zugo-Cel Zugo-cel is an off-the-shelf CD19 CAR-T therapy engineered with CRISPR for immune evasion and potency.
Which conditions is CRISPR Therapeutics targeting with CAR-T?
CRISPR Therapeutics is associated with oncology, rare disease, cardiovascular disease based on its company overview and current catalyst commentary.
How does CRISPR Therapeutics describe recent progress with CAR-T?
FDA review milestones for the pediatric CASGEVY submission covering patients ages 5–11. CTX340 clinical-trial initiation planned in the first half of 2026 and CTX460 trial initiation planned for mid-2026. Clinical update from the Phase 1b CTX310 program expected in the second half of 2026. Updates from the zugo-cel autoimmune and B-cell malignancy programs...
What is Gene-Based?
Gene-Based Medicine Platform CRISPR Therapeutics develops gene-edited medicines across hemoglobinopathies, cardiovascular disease, autoimmune disease, oncology, regenerative medicine and rare disease.